Gastrointestinal neoplasms

1 paper1 finding

Interventions

1

SGLT2 inhibitors

no changein humans1OR 1.1

1 study

SGLT2 inhibitors have no effect on gastrointestinal neoplasms in humans (OR 1.10, 95% CI 0.84-1.44).
Reviewtype 2 diabetes mellitusn = 48,765
Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Clinical and experimental medicine3 Sep 2026

More on SGLT2 inhibitors

Trial sponsors

Pfizer
Company1 trialPhase 3800 people
Intima Bioscience
Company1 trialPhase 1/223 people
Xiaonan Cui
2 trialsPhase 4180 people
Sun Yat-sen University
1 trialPhase 3248 people
German Cancer Research Center
1 trialPhase 260 people
Grupo Espanol de Tumores Neuroendocrinos
1 trialPhase 243 people
Yangzhou University
1 trialPhase 1/2114 people
University Hospital Tuebingen
1 trialPhase 1/2

Latest

1 in 12 months

Clinical and Experimental Medicine3 Sep

Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Meta-analysis of randomised trialsSGLT2 inhibitors